PPAT

Across TCGA pan-cancer cohorts, PPAT RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated PPAT data layer compared with 4 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PPAT RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PPAT expression acts as an unfavorable survival marker, although some lineages such as READ and KIRC show a favorable association.

LIHC, MESO, and READ are the cancer types where PPAT RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.440	0.643	<.001	122	view →
MESO	OS	Tertile	All	0.230	0.535	<.001	90	view →
READ	OS	Median	II,III,IV	0.831	0.407	<.001	84	view →
KICH	DFS	Quartile	II,III,IV	0.445	1.000	.001	68	view →
KIRP	DFS	Quartile	All	0.701	0.950	<.001	66	view →
THCA	OS	Median	II,III,IV	0.755	0.991	<.001	60	view →
CESC	OS	Median	IV	0.091	0.602	.002	58	view →
ACC	DFS	Tertile	All	0.363	0.828	<.001	55	view →
LGG	OS	Median	All	0.719	0.902	<.001	52	view →
KIRC	DFS	Quartile	All	0.816	0.507	.001	46	view →
UCS	OS	Median	III,IV	0.735	0.420	.017	44	view →
UCEC	DFS	Median	All	0.553	0.718	<.001	38	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

PPAT–LIHC (DFS)

Open the LIHC breakdown →